Literature DB >> 27600320

Recommendations for Prevention and Control of Influenza in Children, 2016-2017.

.   

Abstract

The purpose of this statement is to update recommendations for the routine use of seasonal influenza vaccine and antiviral medications for the prevention and treatment of influenza in children. The AAP recommends annual seasonal influenza immunization for everyone 6 months and older, including children and adolescents. Highlights for the upcoming 2016-2017 season include the following: 1. Annual universal influenza immunization is indicated with either a trivalent or quadrivalent (no preference) inactivated vaccine.2. The 2016-2017 influenza A (H3N2) vaccine strain differs from that contained in the 2015-2016 seasonal vaccines. The 2016-2017 influenza B vaccine strain (Victoria lineage) included in the trivalent vaccine differs from that contained in the 2015-2016 seasonal trivalent vaccines (Yamagata lineage). a. Trivalent vaccine contains an A/California/7/2009 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, and a B/Brisbane/60/2008-like virus (B/Victoria lineage). b. Quadrivalent vaccine contains an additional B virus (B/Phuket/3073/2013-like virus [B/Yamagata lineage]).3. Quadrivalent live attenuated influenza vaccine (LAIV4) should not be used in any setting during the 2016-2017 influenza season in light of the evidence for poor effectiveness of LAIV4 in recent seasons, particularly against influenza A (H1N1)pdm09 viruses.4. All children with egg allergy can receive influenza vaccine with no additional precautions from those of routine vaccinations.5. All HCP should receive an annual influenza vaccine, a crucial step in preventing influenza and reducing health care-associated influenza infections. Because HCP may care for or live with people at high risk of influenza-related complications, it is especially important for them to get vaccinated annually.6. Pediatricians should attempt to promptly identify children suspected of having influenza for rapid antiviral treatment, when indicated, to reduce morbidity and mortality.
Copyright © 2016 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27600320     DOI: 10.1542/peds.2016-2527

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  9 in total

1.  The Effectiveness of Trivalent Inactivated Influenza Vaccine in Children with Acute Leukemia.

Authors:  April Sykes; Elsie Gerhardt; Li Tang; Elisabeth E Adderson
Journal:  J Pediatr       Date:  2017-12       Impact factor: 4.406

2.  Live Attenuated and Inactivated Influenza Vaccine Effectiveness.

Authors:  Jessie R Chung; Brendan Flannery; Christopher S Ambrose; Rodolfo E Bégué; Herve Caspard; Laurie DeMarcus; Ashley L Fowlkes; Geeta Kersellius; Andrea Steffens; Alicia M Fry
Journal:  Pediatrics       Date:  2019-01-07       Impact factor: 7.124

3.  Epidemiological factors related to hospitalization due to influenza in children below 6 months of age.

Authors:  J Bustamante; I Calzado; T Sainz; C Calvo; T Del Rosal; A Méndez-Echevarría
Journal:  Eur J Pediatr       Date:  2017-08-29       Impact factor: 3.183

4.  Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons-United States, 2011-2016.

Authors:  Rebekah J Stewart; Brendan Flannery; Jessie R Chung; Manjusha Gaglani; Michael Reis; Richard K Zimmerman; Mary Patricia Nowalk; Lisa Jackson; Michael L Jackson; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Alicia M Fry; Fiona P Havers
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 20.999

Review 5.  AS03- and MF59-Adjuvanted Influenza Vaccines in Children.

Authors:  Amanda L Wilkins; Dmitri Kazmin; Giorgio Napolitani; Elizabeth A Clutterbuck; Bali Pulendran; Claire-Anne Siegrist; Andrew J Pollard
Journal:  Front Immunol       Date:  2017-12-13       Impact factor: 7.561

6.  Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6-35 Months.

Authors:  Jee Hyun Lee; Hye Kyung Cho; Ki Hwan Kim; Jina Lee; Yae Jean Kim; Byung Wook Eun; Nam Hee Kim; Dong Ho Kim; Dae Sun Jo; Hwang Min Kim; Yun Kyung Kim
Journal:  J Korean Med Sci       Date:  2019-12-02       Impact factor: 2.153

7.  Clinical characteristics of influenza virus-induced lower respiratory infection during the 2015 to 2016 season.

Authors:  Kazuhiro Uda; Kensuke Shoji; Chitose Koyama-Wakai; Munehiro Furuichi; Noriyasu Iwase; Seiichiro Fujisaki; Shinji Watanabe; Isao Miyairi
Journal:  J Infect Chemother       Date:  2018-02-09       Impact factor: 2.211

8.  The burden and clinical manifestation of hospitalized influenza among different pediatric age-groups in the tropics.

Authors:  Chia-Yin Chong; Chee-Fu Yung; Cherie Gan; Szu-Tien Thio; Natalie Woon-Hui Tan; Nancy Wen-Sim Tee; Cui Lin; Raymond Tze-Pin Lin; Koh-Cheng Thoon
Journal:  Influenza Other Respir Viruses       Date:  2019-10-13       Impact factor: 4.380

9.  DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.

Authors:  Katherine V Houser; Galina V Yamshchikov; Abbie R Bellamy; Jeanine May; Mary E Enama; Uzma Sarwar; Brenda Larkin; Robert T Bailer; Richard Koup; Myeisha Paskel; Kanta Subbarao; Edwin Anderson; David I Bernstein; Buddy Creech; Harry Keyserling; Paul Spearman; Peter F Wright; Barney S Graham; Julie E Ledgerwood
Journal:  PLoS One       Date:  2018-11-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.